1. |
Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis[J]. Arthritis Care Res (Hoboken), 2012, 64(5):625-639.
|
2. |
杨岫岩, 谢彤. 难治性类风湿性关节炎的治疗[J]. 广东医学, 2001, 22(10):893-894.
|
3. |
Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis[J]. Cochrane Database Syst Rev, 2010 (7):CD008331.
|
4. |
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9):2569-2581.
|
5. |
Md Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis[J]. Drugs, 2013, 73(4):341-356.
|
6. |
王永红, 王可丽, 许素琴, 等. 难治性类风湿关节炎临床特点分 析[J]. 中华风湿病学杂志, 2005, 5(9):171.
|
7. |
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013 update[J]. Ann Rheum Dis, 2014, 73(3):492-509.
|
8. |
Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate:LITHE study 2-year results[J]. J Rheumatol, 2013, 40(2):113-126.
|
9. |
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study):a double-blind, placebo-controlled, randomised trial[J]. Lancet, 2008, 371(9617):987-997.
|
10. |
Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals:results from a 24-week multicentre randomised placebo-controlled trial[J]. Ann Rheum Dis, 2008, 67(11):1516-1523.
|
11. |
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs:the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study[J]. Arthritis Rheum, 2008, 58(10):2968-2980.
|
12. |
Kremer JM, Fleischmann RM, Halland A, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate:the LITHE study[J]. Arthritis Rheum, 2008, 58(12):4031.
|
13. |
史群, 赵岩, 鲍春德, 等. 托珠单抗联合改善病情抗风湿药治疗类风湿关节炎的多中心、随机、双盲、安慰剂对照临床研究[J]. 中华内科杂志, 2013, 52(4):323-329.
|